A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2018 Status changed from recruiting to suspended.
- 02 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.